ADAPTIN BIO, INC.
APTN evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for APTN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · APTN
Adaptin Bio, Inc. is a biotechnology company developing a proprietary technology to enhance the transfer of therapeutics into the brain, with a lead product candidate APTN-101 in an investigator-led Phase 1 trial for glioblastoma multiforme (GBM). The company has no approved products or revenue and faces significant financial and development risks.
Key risk: Cash runway insufficient
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Adaptin Bio, Inc. is a biotechnology company developing a proprietary technology to enhance the transfer of therapeutics into the brain, with a lead product candidate APTN-101 in an investigator-led Phase 1 trial for glioblastoma multiforme (GBM). The company has no approved products or revenue and faces significant financial and development risks.
- Lead product candidate APTN-101 is in a Phase 1 investigator-led trial for glioblastoma multiforme (GBM) [sec_mda · as of 2026-08-13].
- Cash and cash equivalents were $670,488 as of June 30, 2026, down from $459,174 as of December 31, 2025 [sec · filed 2026-08-28].
- Net loss for the six months ended June 30, 2026 was $1,205,312; accumulated deficit reached $11,643,209 as of that date [sec · filed 2026-08-28].
- The company has no revenue from product sales and expects to continue incurring significant operating losses for at least the next several years [sec · filed 2026-08-28].
- Adaptin Bio's technology aims to harness the immune system to target and deliver therapeutics across the blood-brain barrier [sec_mda · as of 2026-08-28].
What works
- The company's proprietary technology targets a significant unmet medical need: delivering therapeutics across the blood-brain barrier for brain cancers and other CNS conditions [sec_mda · as of 2026-08-28].
- APTN-101 is already in a Phase 1 investigator-led trial, indicating some early clinical progress [sec_mda · as of 2026-08-13].
- The platform approach (recombinant, gene therapy, cell therapy) could be applied to multiple indications beyond GBM [sec_mda · as of 2026-08-28].
What to weigh
- Cash and cash equivalents were only $670,488 as of June 30, 2026, which may not be sufficient to fund operations for the next twelve months [sec · filed 2026-08-28].
- The company has an accumulated deficit of $11,643,209 and no revenue from product sales [sec · filed 2026-08-28].
- Clinical development timelines and costs are inherently unpredictable, and the company cannot reasonably estimate when or if it will achieve profitability [sec · filed 2026-08-28].
- The company faces substantial going-concern risks and must raise additional capital to continue operations [sec · filed 2026-08-28].
From the filings
Quoted directly from source documents.
Cash position as of June 30, 2026
“As of December 31, 2025 and June 30, 2026, we had $459,174 and $670,488 in cash and cash equivalents, respectively.”
SEC filings · August 28, 2026
Net loss and accumulated deficit
“2026, we recorded a net loss of $1,205,312 and $2,351,408, respectively. As of June 30, 2026, we had an accumulated deficit of $11,643,209.”
SEC filings · August 28, 2026
Phase 1 trial for GBM
“continue our ongoing and planned development of APTN-101, including pre-clinical activity and our Phase 1 investigator-led trial for the treatment of glioblastoma multiforme ("GBM")”
SEC MD&A · August 13, 2026
Going concern and need for additional funding
“our ability to raise additional money to fund our operations for at least the next twelve months as a going concern”
SEC filings · August 28, 2026
Risks & what to watch (4)›
Key risks
- Cash runway insufficient — With only $670,488 cash as of June 30, 2026, the company may not have enough funds to operate for the next twelve months [sec · filed 2026-08-28].
- No revenue or profitability — The company has no approved products, no product revenue, and expects to incur significant operating losses for several years [sec · filed 2026-08-28].
- Clinical development uncertainty — Timelines and costs for APTN-101 are inherently unpredictable; the company cannot estimate when or if it will obtain marketing approval [sec · filed 2026-08-28].
- Dependence on third parties — The company relies on third parties for drug supply, clinical trials, and manufacturing, which introduces execution risk [sec_mda · as of 2026-05-15].
What to watch
- Progress and results of the Phase 1 investigator-led trial for APTN-101 in GBM [sec_mda · as of 2026-08-13].
- Ability to raise additional capital to fund operations beyond the near term [sec · filed 2026-08-28].
- Any updates on preclinical studies or expansion of APTN-101 into additional indications [sec · filed 2025-02-18].
- Regulatory milestones, including any FDA interactions or IND updates [sec_mda · as of 2026-05-15].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run ADAPTIN BIO, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ADAPTIN BIO, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
5.1 months
OCF -$450K · Net income -$1M
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Financials
Governance
Frequently asked questions
What is the AI investment thesis for ADAPTIN BIO, INC.?
Adaptin Bio, Inc. is a biotechnology company developing a proprietary technology to enhance the transfer of therapeutics into the brain, with a lead product candidate APTN-101 in an investigator-led Phase 1 trial for glioblastoma multiforme (GBM). The company has no approved products or revenue and faces significant financial and development risks.
Who is the CEO of ADAPTIN BIO, INC.?
Dr. Michael J. Roberts Ph.D. is the chief executive officer of ADAPTIN BIO, INC. (APTN).
Where is ADAPTIN BIO, INC. headquartered?
ADAPTIN BIO, INC. (APTN) is headquartered in Charlotte, NC, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.